VVOS vs DBVT vs ALGN vs ALKS vs XRAY

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Align Technology, Inc. at 29. 8x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: ALGN returned +123. 3% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 72β versus DENTSPLY SIRONA Inc. 's 1. 70β — meaning XRAY is approximately 135% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 8. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -74. 1% for Vivos Therapeutics, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -74. 3% for VVOS. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, DENTSPLY SIRONA Inc.

(XRAY) trades at 7. 7x forward P/E versus 14. 8x for Align Technology, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, XRAY (5.

9% yield) pays a dividend. VVOS, DBVT, ALGN, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Align Technology, Inc. (ALGN) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VVOS: -99. 7%, ALGN: +123. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VVOS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALGN is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock. XRAY pays a dividend while VVOS, DBVT, ALGN, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.